explore -WSS

explore

author：fashion 2025-10-02 21:07:02 - browse：9483

Adam's take main illustration — Molly Ferguson/STAT

This week, a preview of the TUDCA study in ALS and thoughts on how it might impact Amylyx Pharmaceuticals. Also, I chatted with CRISPR Therapeutics CEO Sam Kulkarni about its new investor. Read to the end for some burning questions, random thoughts.

The next ALS data readout — overdue but important

A European academic consortium is expected to announce results soon from a clinical trial investigating the use of a widely available nutritional supplement called tauroursodeoxycholic acid, or TUDCA, in people living with ALS. The outcome of the TUDCA-ALS study could have implications for Amylyx Pharmaceuticals, because TUDCA is one of the two main ingredients in Relyvrio, the company’s approved drug for ALS.

In a recent interview at Amylyx’s Kendall Square headquarters, co-CEOs Justin Klee and Josh Cohen mostly downplayed the suggestion that results from the randomized, placebo-controlled TUDCA study might affect Relyvrio negatively, or even positively.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Dobbs anniversary: the lost opportunity of abortion as health care
Next article： Helping hospitals and community health centers plan for resilience

leisure time

Wikipedia

WSS

Robert F. Kennedy is pitching centrism on health, even on abortion

With measles on the rise, a personal story of a devastating disease

A ‘polypill’ could sharply reduce cardiovascular disease in the U.S.

Glen Campbell's doctor discusses his public struggle with Alzheimer's

Doctors' information doesn't help them choose wisely when sick

Medicare Advantage proposed rates disappoint insurers

focus

explore

The next ALS data readout — overdue but important

knowledge

Cancer drug shortages should be causing more outrage

Readout Newsletter: Nvidia, Biogen, Ionis, AstraZeneca, ChatGPT

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Readers respond to H5N1 and livestock movements, and more

Guidelines to prevent youth baseball injuries need more muscle

The dental labor crisis is a moment of opportunity

Heart attack and stroke risk calculators need revising

Venture capitalist Bob Kocher on the state of digital health

Jerome Adams on the need for new antivirals for Covid

Doctors' information doesn't help them choose wisely when sick

knowledge

PhRMA lawsuit over Medicare drug price negotiation tossed

The Readout: Lisata, Eisai x Biogen, and the Met Gala (!)

Wearables generate powerful data but its not useful to doctors, yet

Readout Newsletter: Nvidia, Biogen, Ionis, AstraZeneca, ChatGPT

When prostate cancer spreads, where it goes matters

Arc Institute generative AI designs new CRISPR systems

hotspot

leisure time

Wikipedia

hotspot